DIVISLABPharmaceuticals
Divis Laboratories Ltd — Cash Flow Statement
₹5947.00
-1.42%
Divis Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 215.00 Cr | 258.00 Cr | 1.99K Cr | 1.20K Cr | — |
| Capital Expenditure | -1.44K Cr | -1.00K Cr | -473.00 Cr | -713.20 Cr | — |
| End Cash Position | 413.00 Cr | 363.00 Cr | 170.00 Cr | 1.21K Cr | — |
| Beginning Cash Position | 363.00 Cr | 170.00 Cr | 1.22K Cr | 2.03K Cr | — |
| Changes In Cash | 50.00 Cr | 193.00 Cr | -1.04K Cr | -815.56 Cr | — |
| Financing Cash Flow | -799.00 Cr | -799.00 Cr | -797.00 Cr | -532.44 Cr | — |
| Interest Paid Cff | -2.00 Cr | -2.00 Cr | 0.00 | -0.36 Cr | — |
| Cash Dividends Paid | -796.00 Cr | -796.00 Cr | -796.00 Cr | -530.94 Cr | — |
| Investing Cash Flow | -804.00 Cr | -269.00 Cr | -2.71K Cr | -2.19K Cr | — |
| Interest Received Cfi | 295.00 Cr | 300.00 Cr | 205.00 Cr | 66.81 Cr | — |
| Net Investment Purchase And Sale | 339.00 Cr | 434.00 Cr | -2.44K Cr | -1.55K Cr | — |
| Sale Of Investment | 3.56K Cr | 3.95K Cr | 1.60K Cr | 50.50 Cr | — |
| Purchase Of Investment | -3.22K Cr | -3.52K Cr | -4.04K Cr | -1.60K Cr | — |
| Net PPE Purchase And Sale | -1.44K Cr | -1.00K Cr | -473.00 Cr | -713.20 Cr | — |
| Sale Of PPE | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of PPE | -1.44K Cr | -1.00K Cr | -473.00 Cr | -713.20 Cr | — |
| Operating Cash Flow | 1.65K Cr | 1.26K Cr | 2.46K Cr | 1.91K Cr | — |
| Taxes Refund Paid | -824.00 Cr | -376.00 Cr | -473.00 Cr | -640.98 Cr | — |
| Change In Working Capital | -554.00 Cr | -607.00 Cr | 419.00 Cr | -1.37K Cr | — |
| Change In Other Current Liabilities | 43.00 Cr | 2.00 Cr | -60.00 Cr | 73.25 Cr | — |
| Change In Other Current Assets | -65.00 Cr | -132.00 Cr | 26.00 Cr | -59.41 Cr | — |
| Change In Payable | 95.00 Cr | 62.00 Cr | -34.00 Cr | 34.27 Cr | — |
| Change In Inventory | -52.00 Cr | -184.00 Cr | -172.00 Cr | -683.39 Cr | — |
| Change In Receivables | -582.00 Cr | -361.00 Cr | 650.00 Cr | -741.62 Cr | — |
| Other Non Cash Items | -293.00 Cr | -298.00 Cr | -205.00 Cr | -68.69 Cr | — |
| Provisionand Write Offof Assets | -2.00 Cr | 4.00 Cr | 0.00 | -2.03 Cr | — |
| Depreciation And Amortization | 402.00 Cr | 378.00 Cr | 343.00 Cr | 311.51 Cr | — |
| Amortization Cash Flow | 3.00 Cr | 3.00 Cr | 4.00 Cr | 3.18 Cr | — |
| Depreciation | 399.00 Cr | 375.00 Cr | 339.00 Cr | 308.33 Cr | — |
| Gain Loss On Investment Securities | -5.00 Cr | -5.00 Cr | -4.00 Cr | 2.05 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 9.00 Cr | -2.00 Cr | 10.00 Cr | -3.11 Cr | — |
| Gain Loss On Sale Of PPE | 4.00 Cr | 4.00 Cr | — | — | — |
| Net Income From Continuing Operations | 2.92K Cr | 2.16K Cr | 2.37K Cr | 3.68K Cr | — |
| Net Issuance Payments Of Debt | — | 0.00 | 0.00 | -0.35 Cr | -33.28 Cr |
| Net Short Term Debt Issuance | — | 0.00 | 0.00 | -0.35 Cr | -33.28 Cr |
| Repayment Of Debt | — | — | — | — | -33.28 Cr |
| Short Term Debt Payments | — | — | — | — | -33.28 Cr |
| Dividends Received Cfi | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Divis Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.